Dr James Ehrlich, Dr Ross Walker & Professor Vincenzo Mollace
Our commitment to excellence starts with the BergaMet Medical Team.
We have completed multiple clinical trials and have experts in the field of cardiology based in Italy, Australia and the U.S. who are constantly researching and improving BergaMet products.
Dr James Ehrlich MD
Dr James Ehrlich is a Clinical Associate Professor at the University of Colorado, Denver (Endocrinology) and a former Adjunct Assistant Professor in the Department of medicine at the George Washington University Medical Center in Washington DC. He is the co-founder of the Society of Atherosclerosis Imaging and Society of Cardiovascular CT and is an active contributor to and a task force member of SHAPE- the Society for Heart Attack Prevention and Eradication.
Most of his research has focused on the monitoring of sub-clinical atherosclerosis in insulin resistant states and in Type 1 diabetes. He has experienced significant personal benefit from using BergaMet
Dr. James Ehrlich is the nation’s top authority in new technologies for the early detection of disease and has tested 50,000 Americans at high tech screening centers he founded in 4 US cities. Passionate about prevention and always challenging the “reactive, late disease based model” of healthcare, Ehrlich has become a leading patient advocate arming proactive citizens with strategic advice and the best tools for detecting and preventing our leading and often silent killers.
The first US Ambassador to the BergaMet brand heading up research and recipient of the Accadamia del Bergamotto Award for excellence.
Dr Ross Walker MB, BS (hons) FRACP, FRSANZ
Consultant Cardiologist, emphasis on Preventative Cardiology and Cardiac Imaging, Fellow of the Royal Australian College of Physicians, Member of the Cardiac Society of Australia and New Zealand, Fellow of the Cardiac Society of Australia and New Zealand.
Graduated as a Bachelor of Medicine and Bachelor of Surgery with Honours. Has presented at the American College of Cardiology Meeting. Performed the first mutiplane trans-oesophageal echo-cardiogram in Australia.
Regular lecturer on Preventative Cardiology to a wide range of groups throughout the community. Author of seven books, including several best sellers. He has experience with over 5,000 patients on our product and has had for some 4 years.
Dr Walker has a medical practice in Lindfield on the upper north shore of Sydney. He provides a service in all aspects of echocardiography, focusing on stress echocardiography which is a well accepted, accurate method for assessing heart disease, not involving irradiation or injections. There are presently no other stress echo services on the upper North Shore.
In 1992 Dr Walker commenced stress echocardiography and has since performed 15,000 studies, over 30,000 trans thoracic echoes and 2,000 trans oesophageal echoes.
Dr Ross Walker was recently awarded the prestigious Accadamia del Bergamotto Award in Italy.
Prof. Vincenzo Mollace MD PhD Cardiologist, Pharmacologist
Former Director of the Department of Pharmacology Int San Raffaele IRCCS Rome, Director of Research Institute for Food Safety, UNICZ Consultant at European Medical Agency Committee, for Chair in Pharmacology, Faculty of Biology, UNIVROMA 3 Rome. Full Professor, Faculty of Pharmacy, University of Catanzaro, Italy. Former External Professor of Molecular Pharmacology, University of Rome. Full Professor of Pharmacology and Toxicology at the University of Catanzaro “Magna Graecia”, Italy.
As from 2012, he is also the Director of the International Research Center for Food Safety & Health of Southern Italy, granted by the Italian Ministry of Research with 40 million euro’s for research in Nutraceuticals. His research activity, carried out in many research centers worldwide (mainly the William Harvey Research Institute in London directed by the Nobel Prize Sir John Vane, and Research Fellow and consultant for Cardiovascular Pharmacology at Metaphore Pharm Inc St Louis, USA), that mainly addressed and studied the effect of antioxidant compounds in protecting against atherosclerosis and vascular injury.
Prof. Mollace discovered first, in 2006, the properties of bergamot juice in experimental models of vascular injury published in peer reviewed top ranking scientific journals. For his scientific work, Prof. Mollace was awarded with important international prizes and honour. He has published, to date, more than 100 papers and book chapters in the field of cardiovascular pharmacology.
* Results may vary from person to person. Always consult your Doctor if unsure.
This product does not claim to treat, diagnose or cure any diseases.
BergaMet is a supplement and has not been approved by the FDA.